Oncology News | pharmaphorum

News

Keytruda encroaches on Jemperli's endometrial cancer territo...

Merck & Co's KEYNOTE-158 trial of Keytruda has underpinned another FDA approval, this time for the PD-1 inhibitor as a single-agent therapy as a therapy for endometrial cancer with cert

News

BMS gets FDA OK for first LAG-3 checkpoint inhibitor

Bristol-Myers Squibb has won FDA approval for the first LAG-3 inhibitor drug ahead of its rivals in cancer immunotherapy, including Merck & Co.

News

Merck fights back against Roche in adjuvant lung cancer ther...

Merck & Co's Keytruda is poised to move even earlier in the treatment of patients with non-small cell lung cancer (NSCLC) after showing efficacy when used to prevent the cancer returnin

News

Merck trial of Keytruda, Lynparza combo in prostate cancer f...

Merck & Co's two powerhouse oncology drugs – Keytruda and Lynparza – have failed to show efficacy when used in combination for patients with previously treated metastatic castration-res

News

Belgium's Precirix raises €80m to fund radiopharma aspiratio...

Precirix has raised €80 million ($88 million) in a second-round financing that will be used to advance multiple radiopharmaceutical candidates for cancer through clinical development.

News

Blackstone funds new trials of Sanofi's Sarclisa in myeloma

Sanofi has agreed a deal with life sciences investor Blackstone to help fund clinical trials of a new formulation of Sarclisa for blood cancer multiple myeloma, accelerating its development

Keytruda encroaches on Jemperli's endometrial cancer territo...

BMS gets FDA OK for first LAG-3 checkpoint inhibitor

Merck fights back against Roche in adjuvant lung cancer ther...

Merck trial of Keytruda, Lynparza combo in prostate cancer f...

Belgium's Precirix raises €80m to fund radiopharma aspiratio...

Blackstone funds new trials of Sanofi's Sarclisa in myeloma

Chris McDonald replaces Vallance as UK science minister

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks